Literature DB >> 15032312

Determination of carrier-mediated transport of 2',3'-dideoxypurine nucleosides in the rat ileum using a bidirectional perfusion technique.

R Tyler DeGraw1, Bradley D Anderson.   

Abstract

PURPOSE: Previous attempts to ascertain the role of uptake and efflux transporters in the oral absorption of anti-HIV dideoxypurine nucleosides have been inconclusive. A novel in situ intestinal perfusion technique with complete mesenteric arterial/venous cannulation was used to examine the asymmetry of ileal dideoxynucleoside permeability under near in vivo conditions.
METHODS: Intestinal perfusions were performed in the rat ileum, with cannulation of the artery and vein immediately entering and leaving the segment. Urea and mannitol were used as passive permeability markers, and the directional transport of 2',3'-dideoxyinosine (ddI), 2'-beta-fluoro-2',3'-dideoxyinosine (F-ddI), and 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ddA) were examined.
RESULTS: Urea and mannitol exhibited symmetric permeability (PLtoB = PBtoL), whereas F-ddI and ddI showed significantly higher permeability in blood-to-lumen transport (PBtoL > PLtoB). PBtoL for F-ddA exceeded PLtoB, but the difference did not reach significance at p < 0.05. PBtoL for ddI was demonstrated to be saturable with increasing ddI concentrations, but PLtoB was independent of ddI concentration. PBtoL for ddI was shown to be dependent on sodium concentration and inhibited by probenecid.
CONCLUSIONS: Symmetric transport was demonstrated for urea and mannitol as expected for these passive permeability markers. F-ddI and ddI were shown to be preferentially transported from blood to lumen. The basolateral to luminal transport of ddI is saturable, inhibited by probenecid, and sodium ion dependent. These results are consistent with carrier-mediated uptake on the basolateral membrane.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15032312     DOI: 10.1023/b:pham.0000016243.73161.88

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

1.  Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na+-nucleoside transporters.

Authors:  S D Patil; L Y Ngo; J D Unadkat
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

2.  Expression of sodium-linked nucleoside transport activity in monolayer cultures of IEC-6 intestinal epithelial cells.

Authors:  E S Jakobs; D J Van Os-Corby; A R Paterson
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

3.  Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient.

Authors:  Douglas H Sweet; Lauretta M S Chan; Ramsey Walden; Xiao-Ping Yang; David S Miller; John B Pritchard
Journal:  Am J Physiol Renal Physiol       Date:  2002-12-17

4.  Dose-dependent pharmacokinetics of probenecid in the rat.

Authors:  B M Emanuelsson; L K Paalzow
Journal:  Biopharm Drug Dispos       Date:  1988 Jan-Feb       Impact factor: 1.627

5.  Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in rats.

Authors:  S L Bramer; J L Au; M G Wientjes
Journal:  J Pharmacol Exp Ther       Date:  1993-05       Impact factor: 4.030

6.  Sodium-dependent nucleoside transport in rabbit intestinal epithelium.

Authors:  M Roden; A R Paterson; K Turnheim
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

7.  Differential kinetics of transport of 2',3'-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier.

Authors:  J Y Li; R J Boado; W M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

8.  Hepatic and renal clearances of probenecid in the rat.

Authors:  B M Emanuelsson; L K Paalzow
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

9.  Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog.

Authors:  C A Knupp; W C Shyu; E A Morgenthien; J S Lee; R H Barbhaiya
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

10.  Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Authors:  C A Knupp; W C Shyu; R Dolin; F T Valentine; C McLaren; R R Martin; K A Pittman; R H Barbhaiya
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.